RECIST
Medical abbreviation · Hematology and Oncology
| Stands for | Response Evaluation Criteria in Solid Tumors |
|---|---|
| Categories | Medical |
RECIST stands for Response Evaluation Criteria in Solid Tumors, a hematology and oncology abbreviation.
Standardized rules for measuring how solid tumors respond to treatment on CT or MRI, used in nearly all cancer clinical trials. Up to five target lesions are measured at baseline and on follow-up scans to classify response as complete, partial, stable or progressive.
Example: Per RECIST 1.1, the sum of diameters decreased from 92 mm to 58 mm, a 37% reduction.
Usage notes
First published in 2000 and revised as version 1.1 in 2009, which reduced the number of target lesions and added rules for lymph nodes. Lesions must be at least 10 mm (15 mm short axis for lymph nodes) to be measurable. Adaptations include iRECIST for immunotherapy and mRECIST for liver cancer. Pronounced "REE-sist."
Related abbreviations
More hematology and oncology abbreviations
- PR – Partial response
- PRBC – Packed red blood cells
- PS – Performance status
- PTLD – Post-transplant lymphoproliferative disorder
- PV – Polycythemia vera
- R-CHOP – Rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin)…
- RT – Radiation therapy
- SBRT – Stereotactic body radiation therapy
- SCA – Sickle cell anemia
- SCD – Sickle cell disease
- SCLC – Small cell lung cancer
- SCT – Sickle cell trait
See all 144 hematology and oncology abbreviations →
This entry is for general education and is not medical advice. Abbreviation use varies between institutions; always confirm in context.